As proposed by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention today recommended a single dose of the GSK or Pfizer Respiratory Syncytial Virus vaccine for people aged 60 and older who decide with their health care provider that the vaccine would benefit them. The Food and Drug Administration last month approved the vaccines for use in individuals 60 and older. The first U.S.-licensed vaccines to protect against RSV, they are expected to be available this fall.

Related News Articles

Blog
Exploring and developing a better understanding of the social determinants of health is becoming standard in medical education and training. Social isolation…
Chairperson's File
In today’s episode, I talk with Lynn Todman, vice president of health equity and community partnerships at Corewell Health. Our discussion focuses on the many…
Blog
As a pediatrician, I've seen the impact of pediatric sepsis firsthand — it's an aggressive and unrelenting adversary that knows neither geographic nor…
Headline
The House Energy and Commerce Health Subcommittee March 12 passed AHA-supported  legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care…
Headline
Jonathan Ripp, M.D., chief wellness officer for the Icahn School of Medicine at Mount Sinai and one of the nation’s first, discusses his role and how the…
Headline
Suzanne Bentley, M.D., chief wellness officer at New York City Health and Hospitals Elmhurst, discusses the critical role of peer support in employee mental…